These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18172046)

  • 1. All coronary artery bypass graft surgery patients will benefit from angiotensin-converting enzyme inhibitors.
    Lazar HL
    Circulation; 2008 Jan; 117(1):6-8. PubMed ID: 18172046
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of angiotensin-converting enzyme inhibitors in patients undergoing coronary artery bypass graft surgery.
    Lazar HL
    Vascul Pharmacol; 2005 Feb; 42(3):119-23. PubMed ID: 15792929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient.
    Lazar HL
    Ann Thorac Surg; 2005 Mar; 79(3):1081-9. PubMed ID: 15734453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative angiotensin-converting enzyme inhibitors protect myocardium from ischemia during coronary artery bypass graft surgery.
    Benedetto U; Melina G; Capuano F; Comito C; Bianchini R; Simon C; Refice S; Angeloni E; Sinatra R
    J Cardiovasc Med (Hagerstown); 2008 Nov; 9(11):1098-103. PubMed ID: 18852580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac medical therapy following coronary artery bypass graft surgery.
    Chacko KA
    J Am Coll Cardiol; 2005 Sep; 46(5):934; author reply 934-5. PubMed ID: 16139150
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardioprotective strategies to improve long-term outcomes following coronary artery bypass surgery.
    Arora R; Sowers JR; Saunders E; Probstfield J; Lazar HL
    J Card Surg; 2006; 21(2):198-204. PubMed ID: 16492288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative Angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting.
    Benedetto U; Sciarretta S; Roscitano A; Fiorani B; Refice S; Angeloni E; Sinatra R
    Ann Thorac Surg; 2008 Oct; 86(4):1160-5. PubMed ID: 18805152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac medical therapy post-coronary bypass grafting.
    Osman F; Qaisar S; Pitt M
    J Am Coll Cardiol; 2005 Sep; 46(5):933-4; author reply 934-5. PubMed ID: 16139148
    [No Abstract]   [Full Text] [Related]  

  • 9. Aprotinin and renal dysfunction: the role of exposure to angiotensin-converting enzyme inhibitors.
    Augoustides JG
    J Thorac Cardiovasc Surg; 2008 Oct; 136(4):1104; author reply 1104. PubMed ID: 18954673
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy.
    Brugts JJ; Danser AH; de Maat MP; den Uil CA; Boersma E; Ferrari R; Simoons ML
    Curr Opin Cardiol; 2008 Jul; 23(4):296-301. PubMed ID: 18520711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of perioperative cardiac medical therapy among patients undergoing coronary artery bypass graft surgery.
    Filion KB; Pilote L; Rahme E; Eisenberg MJ
    J Card Surg; 2008; 23(3):209-15. PubMed ID: 18435634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there an "ACE" in the hole for postcoronary artery bypass graft myocardial dysfunction?
    Parrish JS; Amundson DE
    Crit Care Med; 2003 May; 31(5):1591. PubMed ID: 12771645
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors and risk of acute kidney injury after cardiac surgery.
    Bouzas-Mosquera A; Alvarez-García N; Peteiro J
    Ann Thorac Surg; 2009 May; 87(5):1653; author reply 1653-4. PubMed ID: 19379947
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrated care concepts with angiotensin-converting enzyme inhibition: intervention for life. Introduction.
    Zanchetti A
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):67S-68S. PubMed ID: 7818837
    [No Abstract]   [Full Text] [Related]  

  • 15. Should an angiotensin-converting enzyme inhibitor be given at the time of reperfusion therapy in acute myocardial infarction?
    McLachlan CS; Ocsan R; Hambly B; El Oakley R
    Am Heart J; 2008 Jul; 156(1):e1. PubMed ID: 18585486
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of enoximone in patients with low ejection fraction undergoing coronary artery bypass graft surgery.
    Oduro A; Latimer RD; Davies A; Jani K
    Br J Clin Pract Suppl; 1988 Dec; 64():50-2. PubMed ID: 2978500
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal medical management around the time of surgery.
    Voûte MT; Winkel TA; Poldermans D
    Heart; 2010 Nov; 96(22):1842-8. PubMed ID: 20965994
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of angiotensin-converting enzyme inhibitor on hemodynamic instability in patients undergoing cardiopulmonary bypass: results of a dose-comparison study.
    Shahzamani M; Yousefi Z; Frootaghe AN; Jafarimehr E; Froughi M; Tofighi F; Azadani AN; Pourhoseingholi MA; Azadani PN
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):185-91. PubMed ID: 19721131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification after coronary artery bypass surgery by a point-of-care test of platelet function.
    Bevilacqua S; Alkodami AA; Volpi E; Cerillo AG; Berti S; Glauber M; Gianetti J
    Ann Thorac Surg; 2009 Feb; 87(2):496-502. PubMed ID: 19161767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invited commentary.
    Stafford-Smith M
    Ann Thorac Surg; 2008 Oct; 86(4):1165-6. PubMed ID: 18805153
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.